Published in World J Gastroenterol on February 07, 2015
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med (2016) 8.53
SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer. BMC Cancer (2016) 0.77
Unsupervised Analysis of Array Comparative Genomic Hybridization Data from Early-Onset Colorectal Cancer Reveals Equivalence with Molecular Classification and Phenotypes. Neoplasia (2016) 0.75
Downregulation of acetyl-CoA synthetase 2 is a metabolic hallmark of tumor progression and aggressiveness in colorectal carcinoma. Mod Pathol (2016) 0.75
BRAF(V600E) cooperates with CDX2 inactivation to promote serrated colorectal tumorigenesis. Elife (2017) 0.75
Reactivation of CDX2 in Gastric Cancer as Mark for Gene Silencing Memory. Acta Histochem Cytochem (2015) 0.75
CDX2 as a Prognostic Biomarker in Colon Cancer. N Engl J Med (2016) 0.75
Distinct clinical outcomes of two CIMP-positive colorectal cancer subtypes based on a revised CIMP classification system. Br J Cancer (2017) 0.75
Fine-tuning and autoregulation of the intestinal determinant and tumor suppressor homeobox gene CDX2 by alternative splicing. Cell Death Differ (2017) 0.75
Targeted CDX2 expression inhibits aggressive phenotypes of colon cancer cells in vitro and in vivo. Int J Oncol (2017) 0.75
Comprehensive molecular characterization of human colon and rectal cancer. Nature (2012) 34.13
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut (2008) 6.26
Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011. Cancer Res Treat (2014) 5.97
Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol (2005) 5.13
CDX2, a highly sensitive and specific marker of adenocarcinomas of intestinal origin: an immunohistochemical survey of 476 primary and metastatic carcinomas. Am J Surg Pathol (2003) 3.39
A molecular gradient in early Drosophila embryos and its role in specifying the body pattern. Nature (1987) 3.23
Cdx1 and cdx2 expression during intestinal development. Gastroenterology (2000) 3.03
Establishment of intestinal identity and epithelial-mesenchymal signaling by Cdx2. Dev Cell (2009) 2.55
The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clin Cancer Res (2010) 2.23
Structure of the murine homeobox gene cdx-2. Expression in embryonic and adult intestinal epithelium. J Biol Chem (1994) 2.13
Colonic polyposis caused by mTOR-mediated chromosomal instability in Apc+/Delta716 Cdx2+/- compound mutant mice. Nat Genet (2003) 1.99
Loss of CDX2 expression and microsatellite instability are prominent features of large cell minimally differentiated carcinomas of the colon. Am J Pathol (2001) 1.95
The role of Cdx proteins in intestinal development and cancer. Cancer Biol Ther (2004) 1.90
The Cdx2 homeobox gene has a tumour suppressor function in the distal colon in addition to a homeotic role during gut development. Gut (2003) 1.70
Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers. Virchows Arch (2009) 1.67
Cdx2 protein expression in normal and malignant human tissues: an immunohistochemical survey using tissue microarrays. Mod Pathol (2003) 1.50
The homeobox intestinal differentiation factor CDX2 is selectively expressed in gastrointestinal adenocarcinomas. Mod Pathol (2004) 1.44
Metabolome, transcriptome, and bioinformatic cis-element analyses point to HNF-4 as a central regulator of gene expression during enterocyte differentiation. Physiol Genomics (2006) 1.42
Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer. Clin Cancer Res (2009) 1.39
Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev (2008) 1.36
Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod Pathol (2008) 1.30
Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location. Br J Cancer (2013) 1.28
Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features. J Pathol (2011) 1.24
Prognostic value of CpG island methylator phenotype among colorectal cancer patients: a systematic review and meta-analysis. Ann Oncol (2014) 1.21
Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer. Hum Pathol (2011) 1.18
CDX2, a human homologue of Drosophila caudal, is mutated in both alleles in a replication error positive colorectal cancer. Oncogene (1998) 1.17
The intestine-specific transcription factor Cdx2 inhibits beta-catenin/TCF transcriptional activity by disrupting the beta-catenin-TCF protein complex. Carcinogenesis (2009) 1.16
Silencing of CDX2 expression in colon cancer via a dominant repression pathway. J Biol Chem (2003) 1.13
Multiple regulatory regions control the complex expression pattern of the mouse Cdx2 homeobox gene. Gastroenterology (2008) 1.12
Overfitting in prediction models - is it a problem only in high dimensions? Contemp Clin Trials (2013) 1.09
Mapping of HNF4alpha target genes in intestinal epithelial cells. BMC Gastroenterol (2009) 1.08
Expression of MUC2, MUC5AC, MUC5B, and MUC6 mucins in colorectal cancers and their association with the CpG island methylator phenotype. Mod Pathol (2013) 1.04
The human mucin MUC4 is transcriptionally regulated by caudal-related homeobox, hepatocyte nuclear factors, forkhead box A, and GATA endodermal transcription factors in epithelial cancer cells. J Biol Chem (2007) 1.03
Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency. Int J Cancer (2013) 1.02
Demonstration of CDX2 is highly antibody dependant. Appl Immunohistochem Mol Morphol (2013) 0.98
Genomic structure and alterations of homeobox gene CDX2 in colorectal carcinomas. Br J Cancer (1999) 0.97
CDX2 polymorphisms, RNA expression, and risk of colorectal cancer. Cancer Res (2005) 0.91
Aberrant expression of annexin A10 is closely related to gastric phenotype in serrated pathway to colorectal carcinoma. Mod Pathol (2014) 0.89
Reduced CDX2 expression predicts poor overall survival in patients with colorectal cancer. Am Surg (2013) 0.89
Ets transcription factors control epithelial maturation and transit and crypt-villus morphogenesis in the mammalian intestine. Am J Pathol (2009) 0.88
CDX2 mutations do not account for juvenile polyposis or Peutz-Jeghers syndrome and occur infrequently in sporadic colorectal cancers. Br J Cancer (2001) 0.88
Suppression of colonic polyposis by homeoprotein CDX2 through its nontranscriptional function that stabilizes p27Kip1. Cancer Res (2011) 0.88
Regulation of the tumor suppressor homeogene Cdx2 by HNF4α in intestinal cancer. Oncogene (2012) 0.87
The homeobox gene CDX2 in colorectal carcinoma: a genetic analysis. Br J Cancer (2001) 0.87
The clinical perspectives of CDX2 expression in colorectal cancer: a qualitative systematic review. Surg Oncol (2014) 0.87
Loss of Cdx2 Expression in Primary Tumors and Lymph Node Metastases is Specific for Mismatch Repair-Deficiency in Colorectal Cancer. Front Oncol (2013) 0.84
Immunohistochemical analysis of colorectal cancer with gastric phenotype: claudin-18 is associated with poor prognosis. Pathol Int (2010) 0.83
Clinicopathological features of serrated adenocarcinoma defined by Mäkinen in dukes' B colorectal carcinoma. Pathobiology (2012) 0.83
Why have so few proteomic biomarkers "survived" validation? (Sample size and independent validation considerations). Proteomics (2014) 0.82